Triple antithrombotic management after stent implantation: When and how?

Heart

Volumn 95, Issue 15, 2009, Pages 1280-1285

  Schömig, Albert ^a   Sarafoff, Nikolaus ^a   Seyfarth, Melchior ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; PROTON PUMP INHIBITOR; TICLOPIDINE; WARFARIN;

BARE METAL STENT; BLEEDING; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE THROMBOSIS; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVIEW; STENT THROMBOSIS; VENOUS THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEART FAILURE; HEART VALVE PROLAPSE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PLATELET AGGREGATION INHIBITORS; STENTS; VENOUS THROMBOEMBOLISM;

EID: 67650922577     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.160457     Document Type: Review

References (20)

1. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. ▶ The first trial that showed the superiority of DAT over OAC after coronary stent implantation.
2. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-8.
3. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172-209.
4. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54. ▶ This study showed that discontinuation of clopidogrel is a determinant of stent thrombosis only in the first 6 months after stent placement.
5. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28:726-32.
6. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
7. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903- 12. ▶ Large randomised trial that showed for the first time that patients with atrial fibrillation have better outcomes with OAC compared to DAT.
8. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906.
9. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007;146:204-10.
10. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41. ▶ Meta-analysis of risk for thromboembolic complications in patients with mechanical heart valves with various antithrombotic regimens.
11. Schlitt A, von Bardeleben RS, Ehrlich A, et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131-5. ▶ The only trial in humans that compared DAT to OAC in patients with mechanical heart valves. The study was stopped prematurely after one patient on DAT developed aortic valve thrombosis.
12. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
13. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
14. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-25.
15. Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008;264:472-80. ▶ First study that analysed safety and efficacy of triple therapy compared to DAT in patients receiving drug eluting stents only.
16. Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28:1717-22. ▶ Largest number of patients on triple therapy that have been analysed in one study.
17. Rubboli A, Halperin JL, Juhani Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008;40:428-36. ▶ Excellent review of studies on triple therapy and recommendations for management of patients with atrial fibrillation undergoing coronary stenting.
18. Rossini R, Musumeci G, Lettieri C, et al. Outcomes of long-term triple therapy with aspirin, clopidogrel, and warfarin in patients undergoing coronary stenting [abstract]. Eur Heart J 2008; 29(Suppl):328.
19. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909.
20. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60.